Savara (SVRA) | Financial Analysis & Statements
Savara Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-33.4M
Net Income
-32.2M
Balance Sheet Metrics
Total Assets
253.4M
Total Liabilities
50.3M
Shareholders Equity
203.1M
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
-22.4M
Free Cash Flow
-25.1M
Revenue & Profitability Trend
Savara Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 81.4M | 78.0M | 44.3M | 27.9M | 29.0M |
| Selling, General & Administrative | 42.1M | 25.0M | 15.7M | 10.9M | 12.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 123.5M | 103.1M | 59.9M | 38.8M | 41.3M |
| Operating Income | -122.8M | -102.4M | -59.2M | -38.0M | -40.6M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 4.2M | 6.5M | - | - | - |
| Interest Expense | - | - | - | 88.0K | 2.3M |
| Other Non-Operating Income | -236.0K | 51.0K | 76.0K | -19.0K | -99.0K |
| Pre-tax Income | -118.8M | -95.9M | -54.7M | -38.2M | -43.0M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -118.8M | -95.9M | -54.7M | -38.2M | -43.0M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -122.4M | -102.3M | -59.1M | -37.9M | -40.3M |
| EPS (Basic) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 |
| EPS (Diluted) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 |
| Basic Shares Outstanding | 222387531 | 198191936 | 165204652 | 152771817 | 133919145 |
| Diluted Shares Outstanding | 222387531 | 198191936 | 165204652 | 152771817 | 133919145 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Savara Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 33.2M | 15.1M | 26.6M | 52.1M | 34.0M |
| Short-term Investments | 202.5M | 181.2M | 135.7M | 73.8M | 127.2M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 892.0K | 455.0K | 280.0K | 71.0K | 356.0K |
| Total Current Assets | 241.6M | 202.1M | 165.9M | 129.0M | 165.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.0M | 1.9M | 1.8M | 1.8M | 1.8M |
| Goodwill | 11.6M | 10.3M | 11.0M | 10.7M | 11.3M |
| Intangible Assets | 11.6M | 10.3M | 11.0M | 10.7M | 11.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 84.0K | 242.0K | 387.0K | 116.0K | 251.0K |
| Total Non-Current Assets | 11.8M | 10.7M | 11.6M | 10.8M | 11.6M |
| Total Assets | 253.4M | 212.9M | 177.6M | 139.8M | 176.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.8M | 4.5M | 3.5M | 1.3M | 1.4M |
| Short-term Debt | 7.0K | 116.0K | 143.0K | 64.0K | 8.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 362.0K | - | - | - | - |
| Total Current Liabilities | 20.4M | 14.7M | 10.6M | 5.9M | 14.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 29.9M | 26.6M | 26.3M | 26.1M | 17.3M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 87.0K | 247.0K | 54.0K | 117.0K |
| Total Non-Current Liabilities | 29.9M | 26.7M | 26.6M | 26.1M | 17.4M |
| Total Liabilities | 50.3M | 41.4M | 37.2M | 32.0M | 32.1M |
| Equity | |||||
| Common Stock | 204.0K | 173.0K | 140.0K | 116.0K | 116.0K |
| Retained Earnings | -608.1M | -489.2M | -393.4M | -338.7M | -300.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 203.1M | 171.4M | 140.4M | 107.8M | 144.5M |
| Key Metrics | |||||
| Total Debt | 29.9M | 26.7M | 26.5M | 26.1M | 25.8M |
| Working Capital | 221.2M | 187.4M | 155.4M | 123.1M | 150.3M |
Balance Sheet Composition
Savara Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -118.8M | -95.9M | -54.7M | -38.2M | -43.0M |
| Depreciation & Amortization | 87.0K | 130.0K | 175.0K | 167.0K | 367.0K |
| Stock-Based Compensation | 14.4M | 9.9M | 4.2M | 2.0M | 3.3M |
| Working Capital Changes | 4.9M | 4.2M | 4.5M | -376.0K | -1.8M |
| Operating Cash Flow | -99.0M | -81.4M | -45.5M | -36.0M | -40.7M |
| Investing Activities | |||||
| Capital Expenditures | -22.0K | -25.0K | -296.0K | -9.0K | -57.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -204.9M | -204.9M | -194.2M | -89.4M | -161.1M |
| Investment Sales | 186.5M | 165.0M | 137.4M | 142.1M | 91.7M |
| Investing Cash Flow | -18.4M | -39.9M | -57.1M | 52.6M | -69.5M |
| Financing Activities | |||||
| Share Repurchases | -5.1M | -995.0K | -1.2M | -3.0K | -78.0K |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 29.6M | - | 0 | 26.4M | 0 |
| Debt Repayment | -27.2M | - | 0 | -26.4M | 0 |
| Financing Cash Flow | 137.5M | 117.2M | 82.5M | 85.0K | 122.2M |
| Free Cash Flow | -101.1M | -89.1M | -51.4M | -34.6M | -40.1M |
| Net Change in Cash | 20.0M | -4.1M | -20.2M | 16.7M | 12.0M |
Cash Flow Trend
Savara Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.66
Forward P/E
-15.71
Price to Book
6.38
PEG Ratio
-15.71
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-63.45%
Return on Assets
-32.91%
Financial Health
Current Ratio
11.85
Debt to Equity
14.73
Beta
0.31
Per Share Data
EPS (TTM)
$-0.53
Book Value per Share
$0.80
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SVRA | 1.0B | -9.66 | 6.38 | -63.45% | 0.00% | 14.73 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Taysha Gene | 1.8B | 2.53 | 7.39 | -68.45% | 0.00% | 28.41 |
Financial data is updated regularly. All figures are in the company's reporting currency.






